Sergey Young

Sergey Young has some evidence of articulated longevity vision, especially around psychological and biopsychological aging clocks as tools for health assessment, drug development, and therapeutic interventions. The vision is concrete within a narrow aging-biomarker domain and aligns with his longevity-investor identity, but the supplied evidence does not show a broad, durable, public vision for ending aging or materially extending healthy lifespan at field-defining depth.

Evidence shows limited direct scientific impact. The primary citation-metrics source reports modest bibliometrics and no heavily cited field-defining work, while the most-cited works appear unrelated to Sergey Young's longevity role and may reflect an identity match issue. Longevity-relevant output is mainly coauthored conceptual or definitional papers rather than highly cited foundational science or clinical/translational programs.

Capital deployment is applicable because Sergey Young is presented as a longevity-focused venture investor and fund founder. The strongest claim is founding a $100 million Longevity Vision Fund, which would indicate meaningful institution-building and fund allocation toward longevity, but that claim is only supported here by an unknown-independence dossier and is not corroborated by primary or independent evidence in the provided materials. Primary/independent sources only corroborate his affiliation with Longevity Vision Fund and field organizations, not actual deployed amounts, investments, donations, or personal capital at risk.

Strategic_taste applies because Sergey Young is described as a longevity-focused venture investor and founder of longevity-related organizations, but the supplied evidence does not document any specific early, contrarian, thesis-coherent, or counterfactually important bets. The strongest signal is institution-building around longevity, including a $100 million Longevity Vision Fund, but without evidence of target areas, stage, timing, portfolio choices, or field-opening consequences, the strategic-taste case remains weak.

The evidence supports that Sergey Young created longevity-focused funding/organization vehicles, especially Longevity Vision Fund and BOLD Longevity Growth, which fits field_creation. However, the only independent source provided mainly corroborates Longevity Vision Fund as a longevity-sector affiliation and does not independently document founding, scale, activity, or field-level impact. With no evidence of active organizations or donation-created programs, the record supports a moderate but capped score.

The dimension is applicable because Sergey Young is a public longevity investor, but the supplied evidence contains little direct proof of public risk-taking or bravery as defined by the rubric. Founding a $100 million longevity-focused fund shows visible commitment to the field, yet the evidence does not establish that this was contrarian at the time, personally risky relative to capacity, sustained under criticism, or tied to self-experimentation.

Multiplier effect applies because Sergey Young is evidenced as a founder/co-founder of longevity-focused organizations and appears in collaborative longevity publications/field-definition work. However, the supplied evidence gives little direct proof that these activities actually attracted substantial talent, capital, policy attention, collaborators, founders, legitimacy, or follow-on projects. Primary/independent sources corroborate organizational affiliation and collaboration, but not broad second-order leverage at a high level.